{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:33:57Z","timestamp":1793050437185,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Pacing and Electrophysiology Journal"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ipej.2026.10.002","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:44:39Z","timestamp":1791330279000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tafamidis: is it truly a game changer for transthyretin amyloid cardiomyopathy?"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0715-8347","authenticated-orcid":false,"given":"Sarena","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2897-428X","authenticated-orcid":false,"given":"Justin","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandar A.","family":"Aras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ipej.2026.10.002_bib1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American college of cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ipej.2026.10.002_bib2","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.ipej.2026.10.002_bib3","first-page":"712","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC (J Am Coll Cardiol): Heart Fail"},{"issue":"38","key":"10.1016\/j.ipej.2026.10.002_bib4","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"issue":"8853","key":"10.1016\/j.ipej.2026.10.002_bib5","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","article-title":"Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis","volume":"341","author":"Holmgren","year":"1993","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ipej.2026.10.002_bib6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ipej.2026.10.002_bib7","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5607","key":"10.1016\/j.ipej.2026.10.002_bib8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics","volume":"299","author":"Hammarstr\u00f6m","year":"2003","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.ipej.2026.10.002_bib9","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ipej.2026.10.002_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurology and Therapy"},{"key":"10.1016\/j.ipej.2026.10.002_bib11","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/0960-8966(96)88826-2","article-title":"Compound heterozygotes of transthyretin Met 30 and transthyretin Met 119 are protected from the devastating effects of familial amyloid polyneuropathy","volume":"6","author":"Coelho","year":"1996","journal-title":"Neuromuscul Disord"},{"issue":"22","key":"10.1016\/j.ipej.2026.10.002_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM200506023522219","article-title":"Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation","volume":"352","author":"Stangou","year":"2005","journal-title":"N Engl J Med"},{"issue":"5539","key":"10.1016\/j.ipej.2026.10.002_bib13","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","author":"Hammarstr\u00f6m","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ipej.2026.10.002_bib14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/DDDT.S289772","article-title":"Drug discovery and development in rare diseases: taking a closer look at the tafamidis story","volume":"15","author":"Burton","year":"2021","journal-title":"Drug Des Dev Ther"},{"issue":"8","key":"10.1016\/j.ipej.2026.10.002_bib15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ipej.2026.10.002_bib16","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"issue":"2","key":"10.1016\/j.ipej.2026.10.002_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","article-title":"Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis","volume":"8","author":"Damy","year":"2015","journal-title":"J Cardiovasc Transl Res"},{"issue":"3","key":"10.1016\/j.ipej.2026.10.002_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890","article-title":"Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes","volume":"8","author":"Maurer","year":"2015","journal-title":"Circulation Heart Failure"},{"issue":"12","key":"10.1016\/j.ipej.2026.10.002_bib19","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1002\/ejhf.3696","article-title":"Long\u2010term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by national amyloidosis centre stage","volume":"27","author":"Damy","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ipej.2026.10.002_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ipej.2026.10.002_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","article-title":"Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance","volume":"87","author":"Kittleson","year":"2026","journal-title":"JACC (J Am Coll Cardiol)"},{"issue":"15","key":"10.1016\/j.ipej.2026.10.002_bib22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ipej.2026.10.002_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR\u2010ACT) and long\u2010term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ipej.2026.10.002_bib24","series-title":"StatPearls","article-title":"Biochemistry, cytochrome P450","author":"Patel","year":"2026"},{"issue":"15","key":"10.1016\/j.ipej.2026.10.002_bib25","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jaccas.2020.09.037","article-title":"Rhabdomyolysis in the setting of concomitant use of tafamidis, atorvastatin, and amiodarone","volume":"2","author":"Laird","year":"2020","journal-title":"JACC Case Rep"},{"issue":"10","key":"10.1016\/j.ipej.2026.10.002_bib26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ipej.2026.10.002_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ipej.2026.10.002_bib28","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ipej.2026.10.002_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ipej.2026.10.002_bib30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40119-025-00424-6","article-title":"Current and future treatment landscape of transthyretin amyloid cardiomyopathy","volume":"14","author":"Margolin","year":"2025","journal-title":"Cardiology and Therapy"},{"issue":"1","key":"10.1016\/j.ipej.2026.10.002_bib31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.cardfail.2024.10.407","article-title":"Combination therapy versus monotherapy in hereditary transthyretin amyloidosis","volume":"31","author":"Patel","year":"2025","journal-title":"J Card Fail"}],"container-title":["Indian Pacing and Electrophysiology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0972629226002524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0972629226002524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:38:43Z","timestamp":1793047123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0972629226002524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"alternative-id":["S0972629226002524"],"URL":"https:\/\/doi.org\/10.1016\/j.ipej.2026.10.002","relation":{},"ISSN":["0972-6292"],"issn-type":[{"value":"0972-6292","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tafamidis: is it truly a game changer for transthyretin amyloid cardiomyopathy?","name":"articletitle","label":"Article Title"},{"value":"Indian Pacing and Electrophysiology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ipej.2026.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Indian Heart Rhythm Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}